{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = N-Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine
| image = 3-MeO-PCE.svg

<!--Clinical data-->
| tradename = 
| legal_CA = Schedule I
| legal_UK = Class B

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 1364933-80-1
| CAS_supplemental =
| ATC_prefix =
| PubChem = 57461569
| ChemSpiderID_Ref =
| ChemSpiderID      = 58191438
| synonyms = 3-MeO-PCE; Methoxieticyclidine

<!--Chemical data-->
| C=15 | H=23 | N=1 | O=1
| smiles = CCNC1(CCCCC1)C2=CC(=CC=C2)OC
| StdInChI = 1S/C15H23NO/c1-3-16-15(10-5-4-6-11-15)13-8-7-9-14(12-13)17-2/h7-9,12,16H,3-6,10-11H2,1-2H3
| StdInChIKey = OFGOOZLOGUNDFS-UHFFFAOYSA-N
}}

'''3-Methoxyeticyclidine''' ('''3-MeO-PCE'''), also known as '''methoxieticyclidine''',<ref name="pmid24678061">{{cite journal | vauthors = Morris H, Wallach J | title = From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | journal = Drug Test Anal | volume = 6 | issue = 7-8 | pages = 614–32 | year = 2014 | pmid = 24678061 | doi = 10.1002/dta.1620 | url = }}</ref> is a [[dissociative]] [[anesthesia|anesthetic]] that is qualitatively similar to [[Eticyclidine|PCE]] and [[Phencyclidine|PCP]]<ref>{{cite journal|first1=Hamilton|last1=Morris|first2=Jason|last2=Wallach|title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract|journal=Drug Testing and Analysis|date=July–August 2014|issn=1942-7611|pages=614–632|volume=6|issue=7-8|doi=10.1002/dta.1620|pmid=24678061}}</ref> and has been sold online as a [[designer drug]].<ref>{{cite journal|first1=Giorgia De|last1=Paoli|first2=Simon D.|last2=Brandt|first3=Jason|last3=Wallach|first4=Roland P.|last4=Archer|title=From the Street to the Laboratory: Analytical Profiles of Methoxetamine, 3-Methoxyeticyclidine and 3-Methoxyphencyclidine and their Determination in Three Biological Matrices|url=http://jat.oxfordjournals.org/content/37/5/277.full|journal=Journal of Analytical Toxicology|date=June 2013|issn=1945-2403|pages=277–283|volume=37|issue=5|pmid=23552616|doi=10.1093/jat/bkt023|first5=Derrick J.|last5=Pounder}}</ref><ref>{{cite journal|first1=Jason|last1=Wallach|first2=Tristan|last2=Colestock|first3=Brian|last3=Cicali|first4=Simon P.|last4=Elliott|title=Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1861/full|journal=Drug Testing and Analysis|date=August 2016|issn=1942-7611|pages=801–815|volume=8|issue=8|doi=10.1002/dta.1861|pmid=26360516|first5=Pierce V.|last5=Kavanagh|first6=Adeboye|last6=Adejare|first7=Nicola M.|last7=Dempster|first8=Simon D.|last8=Brandt}}</ref><ref>{{Cite web|title=3-MeO-PCE|work=New Synthetic Drugs Database|url=http://nsddb.eu/substance/296/}}</ref>

On October 18, 2012 the [[Advisory Council on the Misuse of Drugs]] in the [[United Kingdom]] released a report about [[methoxetamine]], saying that the "harms of methoxetamine are commensurate with [[Drugs controlled by the UK Misuse of Drugs Act|Class B]] of the [[Misuse of Drugs Act 1971|Misuse of Drugs Act (1971)]]", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.<ref name='ACMD MXE report'>{{cite web|url=https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012|title=Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012|date=18 October 2012|work=UK Home Office}}</ref>

This report also described the receptor binding profile of Methoxetamine and three additional dissociatives [[3-MeO-PCP]], [[4-MeO-PCP]] and 3-MeO-PCE, showing them to have significant affinity for the PCP site of NMDAR and was later published in more detail.<ref name="Roth">{{cite journal|first1=Bryan L.|last1=Roth|first2=Simon|last2=Gibbons|first3=Warunya|last3=Arunotayanun|first4=Xi-Ping|last4=Huang|title=The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor|journal=PLOS ONE|date=March 2013|issn=1932-6203|pages=e59334|volume=8|issue=3|pmid=23527166|pmc=3602154|doi=10.1371/journal.pone.0059334|first5=Vincent|last5=Setola|first6=Ric|last6=Treble|first7=Les|last7=Iversen}}</ref>

3-MeO-PCE has [[Dissociation constant|K<sub>i</sub>]] values of 61 nM for the [[NMDA receptor]], 115 nM for the [[serotonin transporter]], 4519 nM for the [[Sigma-1 receptor|σ<sub>1</sub> receptor]] and 525 nM for the [[Sigma-2 receptor|σ<sub>2</sub> receptor]].<ref name="Roth"/>

==See also==
* [[3-HO-PCP]]
* [[3-MeO-PCMo]]
* [[Arylcyclohexylamine]]
* [[Ketamine]]
* [[Methoxyketamine]]
* [[Eticyclidine]]

==References==
{{reflist|30em}}

{{Hallucinogens}}
{{Ionotropic glutamate receptor modulators}}
{{Sigma receptor modulators}}

[[Category:Dissociative drugs]]
[[Category:O-Methylated phenols]]
[[Category:Designer drugs]]


{{hallucinogen-stub}}
{{pharma-stub}}